406 results about "Viral protein" patented technology

The invention belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a rabbit-derived recombinant monoclonal antibody for specific recognition of type II grass carp reovirus VP4 protein, an eukaryotic expression method and application. According to the invention, a target gene S6 is transfected to an HEK293 cell for expression and purification, a New Zealand white rabbit is immunized in cooperation with a Freund's adjuvant, and the rabbit-derived recombinant monoclonal antibody capable of specifically recognizing the GCRV-II VP4 protein is obtained by using ELISA, single B cell screening and eukaryotic expression technologies. The antibody has strong specificity, provides support for further establishment of a specific II-type grass carp reovirus diagnosis technology, and has great application value in development of GCRV-II related scientific research.

The invention relates to the technical field of biological medicine, in particular to a monoclonal antibody of BRVA virus VP7 protein and an epitope and application of the monoclonal antibody. The invention provides a hybridoma cell strain (preservation number: CCTCC NO: C202570). A monoclonal antibody prepared from the hybridoma cell strain can be combined with VP7 protein of G6, G8 and G10 type BRVA; the antigen epitope amino acid sequence of the monoclonal antibody is SEQ ID NO: 1. The monoclonal antibody and the antigen epitope peptide provided by the invention have broad-spectrum neutralizing activity, and provide a new strategy and tool for prevention and control of BRVA.

The invention belongs to the technical field of biological pharmacy, and particularly relates to influenza virus-like particles for chimeric expression of new coronavirus RBD protein as well as a preparation method and application of the influenza virus-like particles. The virus-like particle is prepared by embedding fusion protein on the surface of influenza virus M1, and the fusion protein comprises an HA2 segment of HA protein of influenza virus, an extracellular functional region of M2e matrix protein, a conserved region short peptide of nucleoprotein, and RBD tandem protein with mutated five sites of 417, 452, 478, 484 and 501 of new coronavirus; the virus-like particles can be used for preventing specific influenza and new crowns; the preparation method of the virus-like particles is simple and low in cost, the virus-like particles are good in immunogenicity and cross protectiveness, the preparation requirements of large-scale influenza vaccines can be met, the biological safety is high, and the immunity of an organism to various influenza viruses and new coronal viruses can be stimulated.

Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.

The invention provides a hybridoma cell strain secreting a grass carp reovirus VP4 protein monoclonal antibody as well as the monoclonal antibody and application thereof, and belongs to the technical field of aquatic reovirus detection. The hybridoma cell strain is named as GCRV-VP4-6E7B12, and is preserved in the China Center for Type Culture Collection on December 10, 2024, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2024160. The grass carp reovirus VP4 protein monoclonal antibody 6E7B12 secreted by the hybridoma cell strain GCRV-VP4-6E7B12 has the advantage of being specifically combined with an antigen. The enzyme-labeled monoclonal antibody is used as a detection antibody, the VP4 protein polyclonal antibody is used as a capture antibody, the content of the grass carp reovirus VP4 protein in a sample to be detected can be quantitatively detected by adopting a double-antibody sandwich ELISA method, the detection range is 1-32 ng / mL, and the lower detection limit is 1 ng / mL. The detection method has the advantages of high sensitivity and wide detection range.

The invention relates to a novel rabies virus nucleocapsid nanostructure vaccine and a construction method thereof, and belongs to the field of biomedicine.The nanostructure vaccine is characterized in that mRNA capable of efficiently expressing rabies virus G protein and recombinant rabies virus N protein expressed by escherichia coli are combined to form an NLS structure serving as a vaccine antigen component; and then wrapping with a lipid component. The vaccine constructed by the invention can form G antigen and N antigen integrated immunogen signal stimulation, so that specific immunity can form an effective reaction in humoral immunity and cellular immunity. In a protective test of challenge, the vaccine can achieve a 100% protection effect on mice.

The present disclosure relates to the expression of recombinant viral antigens using transgenic fungi. Compositions, production and administration of vaccines comprising those viral antigens are also disclosed. In some embodiments, these viral antigens can be used to formulate vaccines against Newcastle disease. These vaccines may be administered, for example, by intramuscular injection.

The invention discloses a specific monoclonal antibody for resisting a Nipah virus Post-F protein, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3; wherein the HCDR1, the HCDR2 and the HCDR3 respectively comprise the HCDR1, the HCDR2 and the HCDR3 in a heavy chain variable region of which the amino acid sequence is any one of SEQ ID NO: 4, 13, 20, 25, 30, 34 or 42, or respectively have at least 85% sequence identity with the HCDR1, the HCDR2 and the HCDR3; and / or the LCDR1, the LCDR2 and the LCDR3 respectively comprise LCDR1, LCDR2 and LCDR3 in a light chain variable region with the amino acid sequence of any one of SEQ ID NO: 9, 16, 23, 28, 32, 37 or 46, or respectively have at least 85% sequence identity with the LCDR1, the LCDR2 and the LCDR3. The anti-Nipah virus Post-F protein monoclonal antibody disclosed by the invention can be specifically combined with a Post-F conformation protein, and has the application potential of being developed into a Nipah virus antibody detection kit or a virus neutralizing antibody drug.

The application belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a rabbit-derived recombinant monoclonal antibody specifically recognizing type II grass carp reovirus VP4 protein, a eukaryotic expression method and application. The S6 gene in GCRV-II encodes VP4 protein, the application transfects the target gene S6 into HEK293 cells for expression and purification, cooperates with Freund's adjuvant to immunize New Zealand white rabbits, and uses ELISA, single B cell screening and eukaryotic expression technology to obtain a rabbit-derived recombinant monoclonal antibody specifically recognizing GCRV-II VP4 protein. The antibody has strong specificity, provides support for further establishment of specific type II grass carp reovirus diagnosis technology, and has great application value for development of GCRV-II related scientific research.

The present invention relates to a respiratory syncytial virus (RSV) F protein reconstructed polypeptide, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a host cell in which the polynucleotide, the nucleic acid construct or the expression vector is transformed or transfected, and a stabilized multimer formed from the reconstructed polypeptide, an immunogenic composition comprising any of the foregoing, and its use in the preparation of a vaccine for the prevention and / or treatment of respiratory syncytial virus infection. The RSV F protein reconstructed polypeptide has good immunogenicity, can stimulate an organism to generate high-level neutralizing antibody titer, and has great significance in clinical treatment and prevention and control of the respiratory syncytial virus.

The invention relates to a virus-like particle for expressing new coronavirus HR121 protein and RBD protein as well as a preparation method and application of the virus-like particle, and belongs to the technical field of vaccines. The invention discloses a recombinant protein combination containing protein 1 and protein 2. The amino acid sequence of the protein 1 is as shown in SEQ ID NO: 5, and the amino acid sequence of the protein 2 is as shown in SEQ ID NO: 8. According to the invention, hepatitis B virus core protein (HBc) virus-like particles are utilized, and an HR121 sequence composed of new crown viruses HR1 and HR2 and RBD are displayed on the surfaces of the virus-like particles in a dimer form, so that the virus-like particles have immunogenicity of proteins of the new crown viruses HR1, HR2 and RBD at the same time, and a stronger protection effect is generated.

The invention discloses a peste des petits ruminants virus specific monoclonal antibody and application thereof.The monoclonal antibody is obtained by screening peste des petits ruminants virus N protein, the amino acid sequence of the peste des petits ruminants virus N protein is shown as SEQ ID NO: 1, the peste des petits ruminants virus N protein is obtained by transcription of a peste des petits ruminants virus N gene, and the peste des petits ruminants virus N gene is shown as SEQ ID NO: 2. The nucleotide sequence of the codon-optimized peste des petits ruminants virus N gene is shown as SEQ ID NO: 2. The monoclonal antibody provided by the invention can be specifically combined with the peste des petits ruminants virus N protein, the titer is high, the affinity is good, meanwhile, the detection kit prepared based on the antibody pair can effectively carry out peste des petits ruminants virus detection, and a technical support can be provided for epidemiological monitoring and diagnosis of peste des petits ruminants virus infection.

The invention provides a porcine deltacoronavirus S1 protein nanoparticle vaccine CTDnps and application thereof, and belongs to the technical field of vaccine preparation. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine capable of being self-assembled, provided by the invention, comprises ferritin and a PDCoV S1 protein C-terminal structural domain, the amino acid sequence of the ferritin is as shown in SEQ ID NO.1, and the amino acid sequence of the PDCoV S1 protein C-terminal structural domain is as shown in SEQ ID NO.2. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine capable of being self-assembled comprises the ferritin and the PDCoV S1 protein C-terminal structural domain. The PDCoV S1 protein C-terminal structural domain nanoparticle vaccine (S1CTD-Fer) constructed by the invention can be self-assembled to form ferritin-like cage-shaped nanoparticles, and the hydrodynamic diameter of the cage-shaped nanoparticles is obviously greater than that of natural ferritin nanoparticles. Compared with the S1CTD, the S1CTD-Fel based on the ferritin carrier can obviously enhance the immunogenicity of the S1CTD, can obviously enhance the uptake efficiency of antigen presenting cells, and is high in safety.

The invention discloses a recombinant yeast for expressing large yellow croaker iridovirus MCP protein and a preparation method and application of the recombinant yeast in preparation of vaccines, and is characterized in that the recombinant yeast is saccharomyces cerevisiae transformed with pYD1-MCP recombinant plasmids and is named as EBY100 / pYD1-MCP, the pYD1-MCP recombinant plasmids can express the MCP protein on a yeast surface display system, the nucleotide sequence of a gene segment of the MCP protein is shown as SEQ ID NO.1, the nucleotide sequence of the gene segment of the MCP protein is shown as SEQ ID NO.2, and the nucleotide sequence of the gene segment of the MCP protein is shown as SEQ ID NO.2. The preparation method comprises a step of constructing a recombinant plasmid pYD1-MCP and a step of constructing a recombinant yeast EBY100 / pYD1-MCP, the oral vaccine of the larimichthys crocea iridovirus vaccine can be prepared, and the oral vaccine has the advantages of being high in protection rate, safe, low in cost, convenient to use and good in application prospect in prevention and control of the larimichthys crocea iridovirus.

The invention discloses a liquid-phase protein chip method for simultaneously detecting three kinds of porcine coronaviruses and a kit thereof, which comprises the following steps of: after activating and coupling microspheres, respectively coating antigen on porcine delta coronavirus N protein, porcine acute diarrhea syndrome coronavirus N protein and porcine epidemic diarrhea virus N protein by using the microspheres; matching the two fluorescent dyes according to different concentrations to form fluorescent coding microsphere combination arrays with different energy levels; the microspheres are analyzed one by one based on the flow principle, red laser recognizes microsphere codes, green laser reads fluorescence intensity of report molecules, computer analysis and processing are carried out, and fluorescence signals are converted into quantitative detection results; and determining the optimization of the detection conditions of the liquid-phase protein chip after the liquid-phase protein chip test. The antigens coated on the microspheres only specifically react with corresponding antibodies and are not combined with antibodies generated by other pathogens; the PDCoV, SADS-CoV and PEDV antibodies in the sample to be detected can be rapidly, effectively and accurately detected, and reference is provided for prevention of the porcine coronavirus.

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention belongs to the technical field of biology, and particularly relates to a swine monoclonal antibody of hog cholera virus Erns protein. The amino acid sequence of a heavy chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 1, the amino acid sequence of a heavy chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 2, the amino acid sequence of a light chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 3, and the amino acid sequence of the light chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 4. The full-length genes of the heavy chain and the light chain of the swine monoclonal antibody are obtained from a swine B cell specifically amplified by the same hog cholera virus Erns protein, the natural structure of an antibody molecule is reserved, affinity loss possibly caused by artificial recombination is avoided, and the swine monoclonal antibody has high affinity and specificity, and can be used for preparing the swine monoclonal antibody. And a precise molecular tool is provided for antigen structure analysis of the hog cholera virus Erns protein and establishment of a hog cholera diagnosis method. The monoclonal antibody is applied to a blocking ELISA detection method of the hog cholera virus Erns antibody, and the established Erns antibody blocking ELISA detection method is high in sensitivity and strong in specificity.

The invention belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a mouse recombinant monoclonal antibody for specifically recognizing African horse pestivirus VP7 protein. According to the invention, a hybridoma cell strain 2C12 for African horse pestivirus VP7 protein is obtained through screening by using a hybridoma cell technology, total RNA is extracted and is subjected to reverse transcription to form cDNA, the cDNA is used as a template and is amplified by using a nested PCR method to obtain light chain and heavy chain variable region sequences of mouse IgG antibody molecules, the light chain and heavy chain variable region sequences are constructed to a plasmid vector containing a mouse source constant region, and the mouse IgG antibody is obtained. And co-transfecting 293F suspension cells for expression and purification to obtain the murine recombinant monoclonal antibody for specifically recognizing the African horse pestivirus VP7 protein. The recombinant antibody can specifically recognize the recombinant VP7 protein of the African horse plague virus, but does not recognize the recombinant VP7 protein of bluetongue virus and epidemic hemorrhagic fever virus, so that support is provided for further establishing a specific African horse plague diagnosis technology.

The invention discloses an Olvapu virus fusion protein, which is formed by connecting and fusing an Olvapu virus Gn protein, an Olvapu virus Gc protein and an Olvapu virus N protein by using GSGSG, and the fusion protein comprises an amino acid sequence as shown in SEQ ID NO.1. The invention further discloses a preparation method of the Olvapu virus fusion protein. The invention also discloses a nucleotide sequence corresponding to the fusion protein, construction of the gene expression vector, a host cell, and a preparation method and application of the fusion protein. Colloidal gold detection test paper for detecting the Oroptovirus antibody in a human body is researched and developed by utilizing the fusion protein, and the test paper has the advantages of high sensitivity, good specificity and high detection accuracy, does not need expensive instruments and equipment at an application end, and has huge clinical significance and wide application prospects.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody 3C7 for detecting BK virus VP1 protein and its applications. The amino acid sequences of the heavy chain variable regions CDR1, CDR2, and CDR3 of the monoclonal antibody are SEQ ID NO. 1–3, and the amino acid sequences of the light chain variable regions CDR1, CDR2, and CDR3 are SEQ ID NO. 4–6, respectively. This antibody exhibits high specificity and can recognize the BK virus VP1 protein. The test strip includes a backing plate, a sample pad, a colloidal gold pad, a nitrocellulose membrane, and absorbent paper. The detection method provided by this invention is simple to operate, highly sensitive, and requires no instruments, enabling rapid and visual detection of BK virus VP1 in urine or recombinant protein samples. It is suitable for on-site screening and point-of-care testing and can supplement existing detection methods such as nucleic acid testing.

The invention discloses preparation and application of a rabies virus G protein mRNA vaccine freeze-drying preparation, and relates to the field of veterinary biological products. According to the invention, rabies virus G protein mRNA is prepared on a large scale through an in-vitro transcription technology, and an mRNA-LNP (lipid nanoparticle) delivery system is successfully constructed by adopting a microfluidic encapsulation process. Through freeze-drying protective agent formula screening (including cane sugar, trehalose and mannitol) and freeze-drying procedure parameter optimization (including pre-freezing temperature, main drying rate and secondary drying residual moisture control), the freeze-dried mRNA vaccine preparation which can stably exist under the condition of 4 DEG C is finally obtained.

The invention belongs to the technical field of antibody preparation, and particularly relates to a recombinant rabbit monoclonal antibody for specifically recognizing type II grass carp reovirus VP56 protein and application of the recombinant rabbit monoclonal antibody. The amino acid sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO.3, and the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO.1. The recombinant rabbit monoclonal antibody for resisting the II type grass carp reovirus VP56 protein prepared by the invention has relatively strong specificity and titer, can specifically recognize the virus VP56 protein in tissues and cells in a natural state, has high affinity for recognizing and combining the virus VP56 protein, has strong anti-interference capability, and can be used for preparing the recombinant rabbit monoclonal antibody for resisting the II type grass carp reovirus VP56 protein. The method is suitable for establishing a high-specificity, high-sensitivity and high-accuracy type II grass carp reovirus diagnosis technology.

The invention relates to a multi-antigen monkey pox RNA vaccine and a preparation method thereof, and relates to the technical field of nucleic acid vaccines. The multi-antigen mRNA comprises a sequence encoding an antigenic polypeptide of the monkey pox virus or an antigenic fragment, variant or derivative thereof, the antigenic polypeptide or the antigenic fragment thereof comprising at least viral proteins of an intracellular mature virus and an extracellular envelope virus of the monkey pox virus. The invention provides a multi-antigen mRNA vaccine aiming at monkey pox viruses and a sequence, mRNA can express antigen protein in in-vitro cells, high-titer anti-monkey pox virus A29L, A33L, B6R, M1R and E8L protein IgG can be detected after a mouse is immunized, a high-titer anti-vaccinia Tian Tan strain live virus neutralizing antibody is generated, good immunogenicity is achieved, and the vaccine can be used for preparing the multi-antigen mRNA vaccine aiming at the monkey pox viruses. The important significance is realized on the prevention of the monkey pox virus.

The invention belongs to the technical field of biological genetic engineering, and particularly relates to a mouse model construction scheme capable of reproducing a key phenotype of hemophagocytic syndrome, which comprises the following steps: inserting a loxP-STOP-loxP-LMP1 conditional expression cassette into a Rosa26 safe port site in a fixed point manner to obtain an Lmp1cKI mouse strain; and hybridizing the mouse with an Ncr1-Cre transgenic mouse of NK cell specific expression Cre recombinase. In a double transgenic offspring (Lmp1Ncr1-Cre), STOP fragments are cut off by Cre enzyme, and continuous high expression of EB virus LMP1 protein in NK cells is driven. The model does not need chemical induction or immune intervention, and typical hemophagocytic syndrome phenotypes, namely serum IL-6, TNF-alpha and IFN-gamma, spontaneously appear within 7-9 days after young rats are born; the body weight is reduced and the survival rate is obviously reduced; the proportion of lymphocytes is sharply reduced; and NK cells are depleted. The invention provides a stable and reliable tool for hemophagocytic syndrome pathogenesis research, drug screening and treatment evaluation.

Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and / or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and / or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus, an immunogenic composition containing the recombinant chimeric antigen and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises two immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122 and ORF060 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and cell outer enveloped virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

The invention provides modified an isolated T lymphocytes having reduced or eliminated expression of the T Cell Receptor, due to reduced or eliminated expression of a CD3ζ, T Cell Receptor Alpha Chain, or T Cell Receptor Beta Chain gene relative to a T lymphocyte without modification, where the isolated T lymphocyte expresses a protein comprising US6, UL40 viral protein and signal peptide, and UL18.

Provided herein is a nucleic acid encoding a prion protein, wherein the prion protein (a) comprises an amino acid sequence comprising a protective sequence variant such as a G127V mutation and (b) lacks a fully functional 3' glycosylphosphatidylinositol (GPI)-anchor attachment sequence. Also provided are viral vectors and pharmaceutical compositions comprising the nucleic acids. Further provided are methods and uses of treating prion diseases or other neurodegenerative diseases that confer toxicity through cell surface- anchored prion proteins in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition or viral vector described herein.

The invention provides a human monoclonal antibody B1AG for resisting type 4 adenovirus. The neutralizing antibody for resisting the 4-type adenovirus provided by the invention can be specifically combined with the 4-type adenovirus, and has very high affinity activity and very strong neutralizing activity at low concentration. The invention also provides application of the antibody in preparation of medicines for treating and / or preventing type 4 adenovirus diseases, and a detection kit containing the antibody.

Provided herein are recombinant polypeptides comprising an engineered ectodomain of a viral protein from enveloped viruses. Also provided herein ar two-component protein nanostructures and compositions for use in vaccinating, generating an immune response, or treating or preventing a viral infection.